Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis : Results From the EuroSpA Research Collaboration Network

Pons, Marion ; Georgiadis, Stylianos ; Hetland, Merete Lund ; Ahmadzay, Zohra Faizy ; Rasmussen, Simon ; Christiansen, Sara N. ; Di Giuseppe, Daniela ; Wallman, Johan K. LU ; Pavelka, Karel and Závada, Jakub , et al. (2025) In Journal of Rheumatology 52(6). p.572-582
Abstract

Objective. In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), as well as treatment continuation after 12 months. Methods. From 11 European registries, patients with axSpA who initiated SEC treatment in routine care, with available data on 6-month ASDAS-CRP and BASDAI assessments were included. Logistic regression analyses on multiply imputed baseline data were performed; potential baseline predictors included demographic,... (More)

Objective. In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), as well as treatment continuation after 12 months. Methods. From 11 European registries, patients with axSpA who initiated SEC treatment in routine care, with available data on 6-month ASDAS-CRP and BASDAI assessments were included. Logistic regression analyses on multiply imputed baseline data were performed; potential baseline predictors included demographic, diagnosis, lifestyle, clinical, and patient-reported variables. Results. In a pooled cohort of 1174 patients with axSpA, 5 of 19 potential assessed variables were mutually predictive for achieving LDA by ASDAS-CRP and BASDAI: higher physician global assessment score, noncurrent smoking, lack of prior exposure to biologic/targeted synthetic disease-modifying antirheumatic drugs, and lower Health Assessment Questionnaire scores and BASDAI scores. Moreover, radiographic axSpA and CRP ≤ 10 mg/L were associated with achieving ASDAS-CRP LDA, and HLA-B27 positivity and history of psoriasis with achieving BASDAI LDA, whereas earlier time of secukinumab initiation (2015-2017) was associated with treatment continuation. Conclusion. In this European real-world study of patients with axSpA initiating SEC, predictors of achieving LDA by ASDAS-CRP and BASDAI at 6 months and remaining on treatment at 12 months included both clinical, patient-reported, and lifestyle factors, underscoring the complex mechanisms of real-world drug effectiveness.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biologic therapy, epidemiology, spondyloarthritis
in
Journal of Rheumatology
volume
52
issue
6
pages
11 pages
publisher
Journal of Rheumatology
external identifiers
  • pmid:39892891
  • scopus:105008271245
ISSN
0315-162X
DOI
10.3899/jrheum.2024-0920
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2025 The Journal of Rheumatology.
id
88d62fe8-053d-4380-84a6-10d127d9d4bb
date added to LUP
2025-12-29 15:52:11
date last changed
2026-01-12 17:31:24
@article{88d62fe8-053d-4380-84a6-10d127d9d4bb,
  abstract     = {{<p>Objective. In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), as well as treatment continuation after 12 months. Methods. From 11 European registries, patients with axSpA who initiated SEC treatment in routine care, with available data on 6-month ASDAS-CRP and BASDAI assessments were included. Logistic regression analyses on multiply imputed baseline data were performed; potential baseline predictors included demographic, diagnosis, lifestyle, clinical, and patient-reported variables. Results. In a pooled cohort of 1174 patients with axSpA, 5 of 19 potential assessed variables were mutually predictive for achieving LDA by ASDAS-CRP and BASDAI: higher physician global assessment score, noncurrent smoking, lack of prior exposure to biologic/targeted synthetic disease-modifying antirheumatic drugs, and lower Health Assessment Questionnaire scores and BASDAI scores. Moreover, radiographic axSpA and CRP ≤ 10 mg/L were associated with achieving ASDAS-CRP LDA, and HLA-B27 positivity and history of psoriasis with achieving BASDAI LDA, whereas earlier time of secukinumab initiation (2015-2017) was associated with treatment continuation. Conclusion. In this European real-world study of patients with axSpA initiating SEC, predictors of achieving LDA by ASDAS-CRP and BASDAI at 6 months and remaining on treatment at 12 months included both clinical, patient-reported, and lifestyle factors, underscoring the complex mechanisms of real-world drug effectiveness.</p>}},
  author       = {{Pons, Marion and Georgiadis, Stylianos and Hetland, Merete Lund and Ahmadzay, Zohra Faizy and Rasmussen, Simon and Christiansen, Sara N. and Di Giuseppe, Daniela and Wallman, Johan K. and Pavelka, Karel and Závada, Jakub and Codreanu, Catalin and Glintborg, Bente and Loft, Anne G. and Santos, Helena and Lourenço, Maria H. and Nissen, Michael J. and Ciurea, Adrian and Kuusalo, Laura and Rantalaiho, Vappu and Michelsen, Brigitte and Mielnik, Pawel and Pirkmajer, Katja P. and Rotar, Ziga and Gudbjornsson, Bjorn and Palsson, Olafur and van der Horst-Bruinsma, Irene and van de Sande, Marleen and Castrejón, Isabel and Macfarlane, Gary J. and Laas, Karin and Østergaard, Mikkel and Ørnbjerg, Lykke M.}},
  issn         = {{0315-162X}},
  keywords     = {{biologic therapy; epidemiology; spondyloarthritis}},
  language     = {{eng}},
  month        = {{06}},
  number       = {{6}},
  pages        = {{572--582}},
  publisher    = {{Journal of Rheumatology}},
  series       = {{Journal of Rheumatology}},
  title        = {{Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis : Results From the EuroSpA Research Collaboration Network}},
  url          = {{http://dx.doi.org/10.3899/jrheum.2024-0920}},
  doi          = {{10.3899/jrheum.2024-0920}},
  volume       = {{52}},
  year         = {{2025}},
}